PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
12.55%
Net income growth similar to AVXL's 13.94%. Walter Schloss would find parallel expansions or market conditions in both firms’ profitability.
-4.31%
Negative yoy D&A while AVXL is 0.00%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
-1173.94%
Negative yoy deferred tax while AVXL stands at 0.00%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
-7.99%
Both cut yoy SBC, with AVXL at -2.61%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
214.02%
Slight usage while AVXL is negative at -22.20%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-138.21%
Both negative yoy AP, with AVXL at -314.29%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
259.96%
Growth well above AVXL's 258.87%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
1173.94%
Well above AVXL's 305.35%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
18.46%
Operating cash flow growth above 1.5x AVXL's 9.85%. David Dodd would confirm superior cost control or stronger revenue-to-cash conversion.
36.17%
CapEx growth of 36.17% while AVXL is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
36.17%
We expand invests by 36.17% while AVXL is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
No Data
No Data available this quarter, please select a different quarter.
-70.77%
Both yoy lines negative, with AVXL at -52.99%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.